Eosinophilic Esophagitis
Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE
The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release.
Eosinophilic Esophagitis: An Update on the Latest Guidelines And Evidence for Improving Patient Outcomes
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Cyted snags FDA 510(k) clearance for non-endoscopic esophageal precancer test
The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.
Immune-resetting peptide gets orphan drug designation for eosinophilic esophagitis
The FDA has granted an orphan drug designation to ’1104 from Revolo Biotherapeutics, a first-in-class immune-resetting peptide designed to treat eosinophilic esophagitis, according to a press release.
Q&A: Improved outcomes anticipated with dupilumab for children with EoE
Treatment options for children with eosinophilic esophagitis have expanded with the FDA’s approval of dupilumab for those aged 1 to 11 years who weigh at least 15 kg, according to a press release.
Top news of January: Dupilumab for eosinophilic esophagitis, cell phone allergy, more
Healio compiled the most-read news in allergy, asthma and immunology posted in January.
FDA approves dupilumab for children with eosinophilic esophagitis
The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release.
Eosinophilic Esophagitis: Optimizing Diagnosis and Treatment – A Wheel of Knowledge Challenge!
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., and Sanofi.
Etrasimod 2 mg reduces peak eosinophil count at week 16, improves symptom severity
VANCOUVER, British Columbia — Once-daily etrasimod 2 mg was well-tolerated and reduced peak eosinophil count at week 16 in patients with eosinophilic esophagitis, according to data presented at the ACG Annual Scientific Meeting.
Dupilumab sustains histologic, endoscopic improvement up to 1 year in children with EoE
VANCOUVER, British Columbia — High-dose dupilumab achieved significant improvements in histologic and endoscopic measures through 52 weeks in children aged 1 to 11 years with eosinophilic esophagitis, according to late-breaking data.